Skip to Content

UK Edition. Click here for US version.

DOCEFIM 80 MG/4 ML CONCENTRATE FOR SOLUTION FOR INFUSION

Active substance(s): DOCETAXEL ANHYDROUS

View full screen / Print PDF » Download PDF ⇩
Transcript
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
Docetaxel 80 mg/4 ml
concentrate for solution for infusion
docetaxel

Read all of this leaflet carefully before you start using this medicine because it contains
important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or your hospital pharmacist or nurse.
- If you get any side effects talk to your doctor, hospital pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. See section 4.
What is in this leaflet:
1. What Docetaxel is and what it is used for
2. What you need to know before you use Docetaxel
3. How to use Docetaxel
4. Possible side effects
5. How to store Docetaxel
6. Contents of the pack and other information

1. WHAT DOCETAXEL IS AND WHAT IT IS USED FOR
The name of this medicine is Docetaxel. Its common name is docetaxel.
Docetaxel is a substance derived from the needles of yew trees.
Docetaxel belongs to the group of anti-cancer medicines called taxoids.
Docetaxel has been prescribed by your doctor for the treatment of breast cancer, special forms of lung
cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
- For the treatment of advanced breast cancer, Docetaxel could be administered either alone or
in combination with doxorubicin, or trastuzumab, or capecitabine.
- For the treatment of early breast cancer with or without lymph node involvement, Docetaxel
could be administered in combination with doxorubicin and cyclophosphamide.
- For the treatment of lung cancer, Docetaxel could be administered either alone or in
combination with cisplatin.
- For the treatment of prostate cancer, Docetaxel is administered in combination with
prednisone or prednisolone.
- For the treatment of metastatic gastric cancer, Docetaxel is administered in combination with
cisplatin and 5-fluorouracil.
- For the treatment of head and neck cancer, Docetaxel is administered in combination with
cisplatin and 5-fluorouracil.
2. WHAT YOU NEED TO KNOW BEFORE YOU USE DOCETAXEL
You must not be given Docetaxel

if you are allergic to docetaxel or any of the other ingredients of this medicine (listed in
section 6).

if the number of white blood cells is too low.

if you have a severe liver disease.
Warnings and precautions
Before each treatment with Docetaxel, you will have blood tests to check that you have enough blood
cells and sufficient liver function to receive Docetaxel. In case of white blood cells disturbances, you
1

may experience associated fever or infections.
Tell your doctor, hospital pharmacist or nurse if you have vision problems. In case of vision problems,
in particular blurred vision, you should immediately have your eyes and vision examined.
If you develop acute or worsening problems with your lungs (fever, shortness of breath or cough),
please tell your doctor, hospital pharmacist or nurse immediately. Your doctor may stop your
treatment immediately.
You will be asked to take premedication consisting of an oral corticosteroid such as dexamethasone,
one day prior to Docetaxel administration and to continue for one or two days after it in order to
minimise certain undesirable effects which may occur after the infusion of Docetaxel in particular
allergic reactions and fluid retention (swelling of the hands, feet, legs or weight gain).
During treatment, you may be given other medicines to maintain the number of your blood cells.
Docetaxel contains alcohol. Discuss with your doctor if you suffer from alcohol dependency or liver
impairment. See also section “Docetaxel contains ethanol (alcohol)” below.
Other medicines and Docetaxel
Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other
medicine, including medicines obtained without a prescription.
This is because Docetaxel or the other medicine may not work as well as expected and you may be
more likely to get a side effect.
Pregnancy, breast-feeding and fertility
Ask your doctor for advice before being given any medicine.
Docetaxel must NOT be administered if you are pregnant unless clearly indicated by your doctor.
You must not become pregnant during treatment with this medicine and must use an effective
method of contraception during therapy, because Docetaxel may be harmful for the unborn baby.
If pregnancy occurs during your treatment, you must immediately inform your doctor.
You must not breast feed while you are treated with Docetaxel.
If you are a man being treated with Docetaxel you are advised not to father a child during and up to 6
months after treatment and to seek advice on conservation of sperm prior to treatment because
docetaxel may alter male fertility.
.
Driving and using machines
No studies on the effects on the ability to drive and use machines have been performed.
Docetaxel contains ethanol (alcohol).

This medicinal product contains approximately 55 vol % ethanol (alcohol), i.e. up to 1.83 g (2.26 ml)
ethanol 96 % per vial of 4 ml fill volume, equivalent to 46 ml beer, 20 ml wine per vial.
Harmful for those suffering from alcoholism.
To be taken into account if you are pregnant or if you are breast feeding women, in children and high
risk groups such as patients with liver disease, or epilepsy.
The amount of alcohol in this medicinal product may alter the effects of other medicines.
2

The amount of alcohol in this medicine may impair your ability to drive or use machines.

3. HOW TO USE DOCETAXEL
Docetaxel will be administered to you by a healthcare professional.
Usual dose
The dose will depend on your weight and your general condition. Your doctor will calculate your
body surface area in square meters (m²) and will determine the dose you should receive.
Method and route of administration
Docetaxel will be given by infusion into one of your veins (intravenous use). The infusion will last
approximately one hour during which you will be in the hospital.
Frequency of administration
You should usually receive your infusion once every 3 weeks.
Your doctor may change the dose and frequency of dosing depending on your blood tests, your
general condition and your response to Docetaxel. In particular, please inform your doctor in case of
diarrhoea sores in the mouth, feeling of numbness or pins and needles, fever and give her/him results
of your blood tests. Such information will allow her/him to decide whether a dose reduction is needed.
If you have any further questions on the use of this medicine, ask your doctor, or hospital pharmacist.

4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Your doctor will discuss these with you and will explain the potential risks and benefits of your
treatment.

The most commonly reported adverse reactions of Docetaxel alone are: decrease in the number of
red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and
tiredness.
The severity of adverse events of Docetaxel may be increased when Docetaxel is given in
combination with other chemotherapeutic agents.
During the infusion at the hospital the following allergic reactions may affect more than 1 in 10
people:
• flushing, skin reactions, itching
• chest tightness; difficulty in breathing
• fever or chills
• back pain
• low blood pressure.
More severe reactions may occur.
The hospital staff will monitor your condition closely during treatment. Tell them immediately if
you notice any of these effects.
Between infusions of Docetaxel the following may occur, and the frequency may vary with the
combinations of medicines that are received:
3

Very common (may affect more than 1 in 10 people):
• infections, decrease in the number of red (anaemia), or white blood cells (which are important in
fighting infection) and platelets
• fever: if this happens you must tell your doctor immediately
• allergic reactions as described above
• loss of appetite (anorexia)
• insomnia
• feeling of numbness or pins and needles or pain in the joints or muscles
• headache
• alteration in sense of taste
• inflammation of the eye or increased tearing of the eyes
• swelling caused by faulty lymphatic drainage
• shortness of breath
• nasal drainage; inflammation of the throat and nose; cough
• bleeding from the nose
• sores in the mouth
• stomach upsets including nausea, vomiting and diarrhoea, constipation
• abdominal pain
• indigestion
• hair loss (in most cases normal hair growth should return)
• redness and swelling of the palms of your hands or soles of your feet which may cause your skin
to peel (this may also occur on the arms, face, or body)
• change in the colour of your nails, which may detach
• muscle aches and pains; back pain or bone pain
• change or absence of menstrual period
• swelling of the hands, feet, legs
• tiredness; or flu-like symptoms
• weight gain or loss.
Common (may affect up to 1 in 10 people):
• oral candidiasis
• dehydration
• dizziness
• hearing impaired
• decrease in blood pressure; irregular or rapid heart beat
• heart failure
• oesophagitis
• dry mouth
• difficulty or painful swallowing
• haemorrhage
• raised liver enzymes (hence the need for regular blood tests).
Uncommon (may affect up to 1 in 100 people):
• fainting
• at the injection site, skin reactions, phlebitis (inflammation of the vein) or swelling
• inflammation of the colon, small intestine; intestinal perforation
• blood clots.
Frequency unknown:
• interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing
• Inflammation of the lungs can also develop when docetaxel therapy is used with radiotherapy)
• pneumonia (infection of the lungs)
• pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath)
• blurred vision due to swelling of the retina within the eye (cystoid macular oedema)
• decrease of the sodium in your blood.
4

Reporting of side effects
If you get any side effects talk to your doctor, hospital pharmacist or nurse. This includes any possible
side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card
Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more
information on the safety of this medicine.

5. HOW TO STORE DOCETAXEL
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on outer carton and on the label of the
vial after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C – 8°C).
Store in the original package in order to protect from light.

Use the vial immediately after its opening. If not used immediately, in-use storage times and
conditions are the responsibility of the user.
From a microbiological point of view, reconstitution/dilution must take place in controlled and aseptic
conditions.
Use immediately the medicine once added into the infusion bag. If not used immediately, in-use
storage times and conditions are the responsibility of the user and would normally not be longer than 8
hours in infusion bottle or 6 hours in infusion bag below 25°C including the one hour infusion.
Physical and chemical in-use stability of the infusion solution prepared as recommended has been
demonstrated in non-PVC bags up to 48 hours when stored between 2 to 8°C.
Docetaxel infusion solution is supersaturated, therefore may crystallize over time. If crystals appear,
the solution must no longer be used and shall be discarded.
Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help protect the environment.

6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Docetaxel contains
-

-

The active substance is docetaxel.
One ml docetaxel concentrate contains 20 mg docetaxel.
The other ingredients are polysorbate 80, ethanol 96% and citric acid monohydrate.

What Docetaxel looks like and contents of the pack
Docetaxel concentrate for solution for infusion is a clear viscous, colourless to brownish-yellow sterile
solution.
The concentrate is supplied in a 4 ml colourless glass vial with a red flip-off closure.
Each box contains one vial of 4 ml concentrate (80 mg docetaxel).

5

Marketing Authorisation Holder
Seacross Pharmaceuticals
Landmark House
17 Hanover Square
Mayfair
LONDON
W1S 1HU
United Kingdom

Manufacturer
IPG Pharma Ltd.
Atrium Court,
The Ring,
Bracknell,
Berkshire,
RG12 1BW,
United Kingdom

This leaflet was last revised in
05/03/2014

6

---------------------------------------------------------------------------------------------The following information is intended for healthcare professionals only:
PREPARATION GUIDE FOR USE WITH Docetaxel 80 mg/4 ml CONCENTRATE FOR
SOLUTION FOR INFUSION
It is important that you read the entire contents of this guide prior to the preparation of the Docetaxel
infusion solution.
RECOMMENDATIONS FOR THE SAFE HANDLING
Docetaxel is an antineoplastic agent and, as with other potentially toxic compounds, caution should be
exercised when handling and preparing its solutions. The use of gloves is recommended.
If Docetaxel concentrate or infusion solution should come into contact with skin, wash immediately
and thoroughly with soap and water. If it should come into contact with mucous membranes, wash
immediately and thoroughly with water.
PREPARATION OF THE INTRAVENOUS ADMINISTRATION
Preparation of the infusion solution
DO NOT use other docetaxel medicinal products consisting of several vials (concentrate and
solvent) with this medicinal product (Docetaxel 80 mg/4 ml concentrate for solution for infusion,
which contains only 1 vial).
Docetaxel 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a
solvent and is ready to add to the infusion solution.
• Each vial is for single use and should be used immediately after opening. If not used immediately,
in use storage times and conditions are the responsibility of the user. More than one vial of
concentrate for solution for infusion may be necessary to obtain the required dose for the patient.
For example, a dose of 140 mg docetaxel would require 7 ml docetaxel concentrate for solution.
• Aseptically withdraw the required amount of concentrate for solution for infusion with a calibrated
syringe.
In Docetaxel 80 mg/4 ml vial the concentration of docetaxel is 20 mg/ml.
• Then, inject via a single injection (one shot) into a 250 ml infusion bag or bottle containing either
5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion. If a dose greater
than 190 mg of docetaxel is required, use a larger volume of the infusion vehicle so that a
concentration of 0.74 mg/ml docetaxel is not exceeded.
• Mix the infusion bag or bottle manually using a rocking motion.
• From microbiological point of view, reconstitution /dilution must take place in controlled and
aseptic conditions and the infusion solution should be used immediately. If not used immediately,
in use storage times and conditions are the responsibility of the user.
Once added as recommended into the infusion bag (PP) or infusion bottle (PE), the docetaxel
infusion solution, if stored below 25°C, is stable for 8 hours in infusion bottle or for 6 hours in
infusion bag. It should be used within 6-8 hours (including the one hour infusion IV
administration).
In addition, physical and chemical in-use stability of the infusion solution prepared as
recommended has been demonstrated in non-PVC bags up to 48 hours when stored between 2°C
to 8°C.
Docetaxel infusion solution is supersaturated, therefore may crystallize over time. If crystals
appear, the solution must no longer be used and shall be discarded.
• As with all parenteral products, infusion solution should be visually inspected prior to use,
solutions containing a precipitate should be discarded.
7

DISPOSAL
All materials that have been utilised for dilution and administration should be disposed of according to
standard procedures. Do not throw away any medicines via wastewater. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the environment.

8

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide